Enhertu Significantly Improves Quality of Life for Metastatic Breast Cancer Patients
Enhertu and Quality of Life in Metastatic Breast Cancer
In the realm of breast cancer treatment,
patients facing metastatic breast cancer (MBC) have a new beacon of hope with Enhertu (trastuzumab deruxtecan). Recent data presented at the 2024 ESMO Congress indicates that patients receiving
Key Findings from the Study
- Enhertu improved median time to deterioration for pain, with 22 months compared to 6.3 months for TPC.
- Reduction in risks of deterioration in physical functioning and quality of life (QOL) was noted.
- Among the treatment arms, Enhertu showed sustained QOL scores over a 31-week observation period.
As stated by Dr. Xichun Hu, the DESTINY-Breast06 trial focused on patients with HR-positive and HER2-low MBC, who had previously undergone several lines of treatment. With a mean baseline Global Health Status score of 69.51 in the Enhertu group, the changes in QOL over time remained insignificant, emphasizing the treatment's stability.
Safety and Side Effects
While Enhertu demonstrated an overall positive impact on quality of life, some side effects such as nausea and constipation were noted. Therefore, implementing supportive care such as antiemetic prophylaxis in clinical practice remains essential.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.